fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

United Therapeutics to showcase innovations and insights in pulmonary hypertension at PVRI 2025

Written by | 22 Jan 2025

United Therapeutics Corporation a public benefit corporation, announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular… read more.

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

Written by | 21 Jan 2025

Boston Scientific Corporation (announced data supporting the use of the FARAPULSE Pulsed Field Ablation (PFA) System  during a late-breaking science session at AF Symposium 2025. Currently, the FARAPULSE… read more.

Bayer submits application to the FDA and to China’s CDE for new indication of finerenone for patients with common form of heart failure with high unmet medical need

Written by | 20 Jan 2025

Bayer announced the submission of marketing authorization applications to the FDA and to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval… read more.

Exceptional launch for Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease – Verona Pharma

Written by | 15 Jan 2025

Verona Pharma plc  announces preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. “2024 was another… read more.

European Commission approves extended indication for Palforzia (defatted powder of Arachis hypogaea L semen (peanut)) for toddlers with a confirmed diagnosis of peanut allergy – Stallergenes Greer

Written by | 14 Jan 2025

Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia  (defatted powder of Arachis hypogaea L.,… read more.

New data from three oral presentations, showing significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma patients presented at ASH meeting – Sanofi

Written by | 11 Jan 2025

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th American Society… read more.

FDA approves Tryngolza (olezarsn) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome – Ionis Pharma

Written by | 9 Jan 2025

Ionis Pharmaceuticals, Inc.  announced  that the FDA has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare,… read more.

Marinus regains commercial rights in Europe for ganaxolone from Orion Pharma

Written by | 8 Jan 2025

30 December 2024-Orion Corporation  and Marinus Pharmaceuticals, Inc. have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone. Marinus regains ganaxolone’s commercial rights in… read more.

European Commission approves Yselty (linzagolix) for the symptomatic treatment of endometriosis – Theramex

Written by | 7 Jan 2025

Theramex, a global pharmaceutical company dedicated to women’s health, is pleased to announce that the European Commission (EC) has approved an extended indication for Yselty (linzagolix), an oral… read more.

NICE (UK) positive for Zepbound (tirzepatide) for managing overweight and obesity – Eli Lilly

Written by | 6 Jan 2025

NICE (UK): 1.1 Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:… read more.

Medtronic announces strongly positive results for patients from procedural and design innovation of Evolut TAVR

Written by | 5 Jan 2025

Medtronic plc announced new data for the Evolut Transcatheter Aortic Valve Replacement System (TAVR) at PCR London Valves 2024. This new clinical evidence brings further insights to global… read more.

Supplemental approval of Opdivo + cisplatin + gemcitabine for treatment of unresectable urothelial carcinoma in Japan – Ono Pharma

Written by | 4 Jan 2025

Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.  announced that Ono has received a supplemental approval of Opdivo (generic name: nivolumab) Intravenous Infusion (“Opdivo”), an anti-PD-1 antibody, in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.